Altria Releases Financial Report for Q4 2023 and Full Year, Net Revenue Reaching $24.48 Billion for 2023

Business by 2FIRSTS.ai
Feb.02.2024
Altria Releases Financial Report for Q4 2023 and Full Year, Net Revenue Reaching $24.48 Billion for 2023
Tobacco company Altschuyler reported a 2.2% decrease in Q4 and 2.4% decrease in full-year net revenues for 2023.

Altria Corporation, the official website, recently released its financial report for the fourth quarter and full year of 2023.

 

Altriai's net revenue in the fourth quarter of 2023 amounted to $5.98 billion, with a total net revenue of $24.48 billion for the entire fiscal year. This represents a decrease of 2.2% and 2.4% compared to the same period in 2022, respectively. The adjusted earnings per share for the fourth quarter remained unchanged at $1.18, as compared to the previous year.

 

According to a report released by ABC Company, the overall decline in net income was primarily attributed to a decrease in the revenue of the combustible tobacco products division. This decrease partially offset the increase in net income observed in the oral tobacco products division.

 

Ocheria expects its adjusted earnings per share for the full year of 2024 to be within the range of $5.00 to $5.15. This represents a growth rate of 1% to 4% compared to the baseline of $4.95 in 2023.

 

Billy Gifford, Chief Executive Officer of Orchia, has stated that electronic vaping products continue to be the most popular smoke-free products, with a growth of approximately 35% last year. However, a significant portion of this growth comes from illegally flavored disposable products, which account for half of the market share. Gifford stated, "The current state of the market is unacceptable for both legitimate manufacturers and consumers. These products are distributed by companies that have violated almost all regulations and guidelines issued by the US Food and Drug Administration since 2016.

 

Investors should take note that Altriai has enhanced shareholder returns through share buybacks and dividend payments.

 

In 2023, Ochiya repurchased 22.7 million shares at an average price of $43.96, returning $1 billion in cash to shareholders. The company's board of directors has now authorized a new $1 billion stock repurchase plan, expected to be completed by the end of 2024.

 

In August of last year, AAltria increased its dividend by 4.3%, marking the 58th dividend growth in the past 54 years. According to the financial report, dividends paid in the fourth quarter amounted to $1.7 billion, while dividends projected for 2023 are estimated at $6.8 billion.

 

In 2018, Altria acquired a 35% stake in e-cigarette company JUUL Labs for a total investment of $12.8 billion. However, the company faced legal challenges related to youth smoking as JUUL was accused of aggressively targeting the teenage market.

 

As of the end of 2022, Altria's valuation of JUUL has plummeted to only $250 million.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

2Firsts Compliance Solutions Hosts PMTA Briefing on FDA Review Signals After JUUL2 Authorization
2Firsts Compliance Solutions Hosts PMTA Briefing on FDA Review Signals After JUUL2 Authorization
Following recent FDA authorizations for JUUL2 and ZYN ULTRA, 2Firsts Compliance Solutions held an online PMTA briefing on Sept. 4 to examine what the decisions may signal about review efficiency, scientific evidence and U.S. market access. Nearly 30 participants from brands, manufacturers, compliance service providers and investment firms joined the discussion.
2Firsts Events
Sep.06
Product | PMI Japan Launches SENTIA Passion Fruit Capsule, Expanding the IQOS ILUMA Flavor Portfolio
Product | PMI Japan Launches SENTIA Passion Fruit Capsule, Expanding the IQOS ILUMA Flavor Portfolio
Philip Morris Japan (PM Japan) has introduced SENTIA Passion Fruit Capsule, a new tobacco stick designed for the IQOS ILUMA heated tobacco platform. Featuring a crush-activated capsule, the product combines menthol with passion fruit flavor to provide an additional flavor experience. The product launched in Japan from August 3, 2026, through IQOS official channels, convenience stores and tobacco retailers.
Aug.04
2Firsts Hosts U.S. Market Mid-Year Briefing: Companies Need to Reassess Product and Market-Access Strategies
2Firsts Hosts U.S. Market Mid-Year Briefing: Companies Need to Reassess Product and Market-Access Strategies
2Firsts held its 2026 U.S. Market Compliance and Development Mid-Year Briefing in Shenzhen, China, on July 28. The discussion examined how state-level requirements, proposed foreign-establishment registration rules and expanding supply-chain responsibilities are changing product and investment decisions in the U.S. tobacco and nicotine market.
Jul.29
As FDA Reshapes PMTA Reviews and ENDS Enforcement Priorities, CTP Acting Director Bret Koplow to Keynote NATO Event for a Retail Network of 66,000-Plus Stores
As FDA Reshapes PMTA Reviews and ENDS Enforcement Priorities, CTP Acting Director Bret Koplow to Keynote NATO Event for a Retail Network of 66,000-Plus Stores
Bret Koplow, acting director of the U.S. Food and Drug Administration's Center for Tobacco Products, will deliver a keynote and participate in a fireside chat at the National Association of Tobacco Outlets' Sept. 29-30 conference in Washington. His appearance comes months after the FDA moved to accelerate PMTA reviews and introduced a more differentiated enforcement policy for certain unauthorized ENDS and oral nicotine pouch products. The agency also plans a public list identifying manufacturers and products it does not currently intend to prioritize for enforcement under the May guidance. NATO says its membership includes more than 66,000 retail stores, making product-status transparency and enforcement boundaries directly relevant to the retail sector.
Aug.14
Philippine Local Governments Urge Marcos to Prioritize Smoke- and Vape-Free Bill
Philippine Local Governments Urge Marcos to Prioritize Smoke- and Vape-Free Bill
The League of Municipalities of the Philippines (LMP) has urged President Ferdinand Marcos Jr. to prioritize the Smoke- and Vape-Free Bill, seeking a nationwide legal framework for tobacco and vape regulation. Local government leaders said national legislation would help standardize enforcement and strengthen public health measures. The proposal remains at the advocacy stage and has not yet become law.
Jul.29
Product | PMI Japan Expands ZYN by IQOS Strength Portfolio With Strong Series, Increasing Lineup to 12 Products
Product | PMI Japan Expands ZYN by IQOS Strength Portfolio With Strong Series, Increasing Lineup to 12 Products
Philip Morris Japan (PMJ) has expanded the ZYN by IQOS oral tobacco pouch portfolio in Japan with four new ZYN Strong products, adding a third intensity level alongside the existing Low and Medium ranges. The Strong series first entered selected duty-free channels in Japan on July 1, 2026, before expanding to IQOS stores, the ZYN Online Store and selected tobacco retailers from August 18. The expansion increases the Japanese ZYN by IQOS lineup from eight to 12 products.
Aug.20